Cara Therapeutics Newsroom

Cara Therapeutics Analyst Ratings

BenzingaJun 13 06:08 ET

Canaccord Genuity Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10

MT NewswiresJun 13 05:47 ET

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)

TipRanksMay 23 06:45 ET

Cara Therapeutics Analyst Ratings

BenzingaMay 23 06:27 ET

Cara Therapeutics Analyst Ratings

BenzingaMay 15 12:01 ET

HC Wainwright & Co. Reiterates Buy on Cara Therapeutics, Maintains $3.6 Price Target

BenzingaMay 15 11:38 ET

Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Iterum Therapeutics (ITRM) and Cara Therapeutics (CARA)

TipRanksMay 14 11:25 ET

Cara Therapeutics Analyst Ratings

BenzingaMay 14 11:07 ET

Cara Therapeutics: A Buy Rating Ahead of Key Oral Difelikefalin Trial Results

TipRanksMay 14 07:41 ET

Cara Therapeutics (CARA) Gets a Buy From Stifel Nicolaus

TipRanksMay 14 07:15 ET

Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment

TipRanksApr 12 06:20 ET

Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential

TipRanksApr 10 06:41 ET

Cara Therapeutics Analyst Ratings

BenzingaApr 10 06:37 ET

Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)

TipRanksMar 28 06:06 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 28 05:40 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 6 06:58 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 5 06:32 ET

Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating

TipRanksMar 5 06:00 ET

Cara Therapeutics Analyst Ratings

BenzingaJan 22 17:06 ET

Strategic Restructuring and Focus on NP Program Justify Buy Rating for Cara Therapeutics

TipRanksJan 22 15:22 ET